Wei Gan*

Dr. Wei Gan*


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2025 in Lipids in Health and Disease
Verified
Journal Article
Open access
PDF file
BFBin Feng
Bin Feng
YWYi Wang
Yi Wang
JXJingjie Xu
Jingjie Xu
LSLiang Sang
Liang Sang
YZYanhua Zhao
Yanhua Zhao
WGWei Gan*
Wei Gan*
This study aimed to (1) evaluate small dense low-density lipoprotein cholesterol (sdLDL-C) dynamics from prediabetes to type 2 diabetes mellitus (T2DM) with complications, (2) validate existing sdLDL-C estimation formulas (Sampson’s, Srisawasdi’s, Han’s) in Chinese populations, and (3) develop a population-specific formula for enhanced accuracy. A multicenter study recruited 1,944 participants (216 controls, 70 with prediabetes, 212 with newly diagnosed T2DM, 164 with treated T2DM, and 1,286 in validation cohorts). Lipid profiles, including sdLDL-C (measured via enzymatic assays), were analyzed. Formula performance was assessed using spearman correlation, intraclass correlation coefficients (ICC), and multivariable linear regression. A novel formula was derived via multivariable regression. Atherogenic lipid triad manifestations emerged early: sdLDL-C was significantly elevated in participants with prediabetes (1.07 [0.73, 1.40] vs. 0.57 [0.44, 0.72] mmol/L in controls, P < 0.05) and further increased in those with T2DM, correlating strongly with triglycerides (TG; r = 0.59), non-high-density lipoprotein cholesterol (nonHDL-C; r = 0.69), and apolipoprotein B (ApoB; r = 0.62). Existing formulas overestimated sdLDL-C in controls and treated T2DM (P < 0.05), though both Han’s and Sampson’s formula performed better in newly diagnosed T2DM (P > 0.05). A novel sdLDL-C estimation formula, incorporating low-density lipoprotein cholesterol (LDL-C), TG, nonHDL-C, age, and sex, achieved superior accuracy (R²=0.743; ICC = 0.681) and minimized residuals (Δ = 0.16 vs. 0.28–0.29, P < 0.05). sdLDL-C elevation begins in prediabetes, highlighting its value for early atherosclerotic cardiovascular disease (ASCVD) risk assessment. Current formulas show population-specific limitations, whereas the new model provides improved accuracy for Chinese T2DM patients, enabling cost-effective sdLDL-C estimation and personalized lipid management.

27 November 2025 in World Journal of Hepatology
Verified
Journal Article
Open access
YZYan-Hua Zhao
Yan-Hua Zhao
SLShu-Sheng Leng
Shu-Sheng Leng
YWYan Wang
Yan Wang
FKFa-Zhi Kui
Fa-Zhi Kui
WGWei Gan*
Wei Gan*
Metabolic dysfunction-associated steatotic liver disease (MASLD) requires accurate liver fibrosis assessment for management. While liver biopsy remains the gold standard, its invasiveness drives demand for non-invasive biomarkers. This review evaluates blood biomarkers for MASLD fibrosis staging. Established scores (fibrosis-4, non-alcoholic fatty liver disease fibrosis score) offer accessible screening but exhibit variable performance influenced by age, obesity, and comorbidities. Patented panels (e.g. , enhanced liver fibrosis test, FibroMeter) improve accuracy by integrating extracellular matrix or metabolic markers, though context-specific thresholds are essential. Emerging biomarkers like propeptide of type 3 collagen, Mac-2 binding protein glycosylation isomer, epigenetic markers (proliferator-activated receptor-γ methylation), and angiopoietin-like proteins a family of eight glycoproteins show promise but require large-scale validation. Genetic risk scores and multi-omics approaches face generalizability challenges. Integration strategies, such as combining serum biomarkers with liver stiffness measurement via Agile scores, enhance diagnostic precision and reduce indeterminate classifications. Current tools aid risk stratification, but no single biomarker replicates biopsy-level precision. Future efforts must prioritize MASLD-specific diagnostic frameworks, standardized protocols, and multi-modal integration to enhance clinical utility and address MASLD’s growing burden.

6 September 2024 in Annals of Medicine
Verified
Journal Article
Open access
AZAnjiang Zhao
Anjiang Zhao
YLYanyang Liu
Yanyang Liu
JXJunxiang Xia
Junxiang Xia
LHLan Huang
Lan Huang
QLQing Lu
Qing Lu
WGWei Gan*
Wei Gan*
At the beginning of December 2022, the Chinese government made major adjustments to the epidemic prevention and control measures. The epidemic infection data and laboratory makers for infected patients based on this period may help with the management and prognostication of COVID-19 patients. The COVID-19 patients hospitalized during December 2022 were enrolled. Logistic regression analysis was used to screen significant factors associated with mortality in patients with COVID-19. Candidate variables were screened by LASSO and stepwise logistic regression methods and were used to construct logistic regression as the prognostic model. The performance of the models was evaluated by discrimination, calibration, and net benefit. 888 patients were eligible, consisting of 715 survivors and 173 all-cause deaths. Factors significantly associated with mortality in COVID-19 patients were: lactate dehydrogenase (LDH), albumin (ALB), procalcitonin (PCT), age, smoking history, malignancy history, high density lipoprotein cholesterol (HDL-C), lactate, vaccine status and urea. 335 of the 888 eligible patients were defined as ICU cases. Seven predictors, including neutrophil to lymphocyte ratio, D-dimer, PCT, C-reactive protein, ALB, bicarbonate, and LDH, were finally selected to establish the prognostic model and generate a nomogram. The area under the curve of the receiver operating curve in the training and validation cohorts were respectively 0.842 and 0.853. In terms of calibration, predicted probabilities and observed proportions displayed high agreements. Decision curve analysis showed high clinical net benefit in the risk threshold of 0.10-0.85. A cutoff value of 81.220 was determined to predict the outcome of COVID-19 patients via this nomogram. The laboratory model established in this study showed high discrimination, calibration, and net benefit. It may be used for early identification of severe patients with COVID-19.

26 August 2023 in Clinica Chimica Acta
Verified
Journal Article
Closed access
CZChuan Zheng
Chuan Zheng
WZWeiyan Zhou
Weiyan Zhou
RZRuyi Zhou
Ruyi Zhou
HZHe Zhang
He Zhang
SLShanshan Liang
Shanshan Liang
WGWei Gan*
Wei Gan*

1 March 2026 in Analytica Chimica Acta
Verified
Journal Article
Closed access
HZHe Zhang
He Zhang
JCJueping Chen
Jueping Chen
YCYuxuan Chen
Yuxuan Chen
ZYZi Yang
Zi Yang
QYQian Yang
Qian Yang
WGWei Gan*
Wei Gan*

5 August 2024 in Clinica Chimica Acta
Verified
Journal Article
Closed access
YZYanhua Zhao
Yanhua Zhao
HZHe Zhang
He Zhang
SLShanshan Liang
Shanshan Liang
YWYan Wang
Yan Wang
WGWei Gan*
Wei Gan*